The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.

The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

More than half of patients with fingernail psoriasis achieved complete fingernail clearance after 68 weeks of guselkumab treatment.

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Janssen has filed its psoriasis injection guselkumab in the US, one of a crop of new drugs it hopes will each exceed $1 billion in sales. The Johnson & Johnson unit is seeking approval for ...

Your provider may also recommend biologics like Remicade (infliximab), Humira (adalimumab), Cosentyx (secukinumab), and Tremfya (guselkumab) for more severe cases of psoriasis. Another option is ...

Janssen’s Tremfya (guselkumab) psoriasis drug has been launched in the UK, where it hopes to steal sales from a crowd of well-established drugs such as Novartis’ Cosentyx. The launch in ...

US pharma major Johnson & Johnson (NYSE: JNJ) has won US approval for Tremfya (guselkumab) in the treatment of adults with ...

Medically reviewed by Susan Bard, MD Rosacea, psoriasis, and eczema share some symptoms, such as rashes, bumps, redness, and itching. However, they are different conditions, though it is possible to ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the ...